Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose

Lancet Infect Dis. 2025 Jan 14:S1473-3099(25)00005-2. doi: 10.1016/S1473-3099(25)00005-2. Online ahead of print.

¹ Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra Pin-411021, India. Electronic address: [email protected].
² Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra Pin-411021, India.

No abstract available